Amphastar Pharmaceuticals, Inc.
AMPH
$28.76
-$0.05-0.17%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.13% | 24.34% | 23.11% | 12.57% | 15.28% |
| Total Other Revenue | -102.03% | -91.66% | -- | -- | -- |
| Total Revenue | 4.73% | 5.90% | 25.17% | 22.72% | 31.91% |
| Cost of Revenue | 21.85% | 23.73% | 19.53% | 28.75% | 28.36% |
| Gross Profit | -9.87% | -5.96% | 30.83% | 17.72% | 35.09% |
| SG&A Expenses | 7.46% | 24.95% | 17.36% | 21.63% | 35.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.90% | 24.37% | 16.87% | 19.19% | 27.71% |
| Operating Income | -16.37% | -21.51% | 49.66% | 32.87% | 42.68% |
| Income Before Tax | 7.64% | -24.61% | 54.56% | 44.29% | -0.88% |
| Income Tax Expenses | 28.35% | -48.28% | 92.61% | -38.89% | -35.90% |
| Earnings from Continuing Operations | 4.97% | -17.86% | 45.26% | 65.86% | 6.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.97% | -17.86% | 45.26% | 65.86% | 6.65% |
| EBIT | -16.37% | -21.51% | 49.66% | 32.87% | 42.68% |
| EBITDA | -12.31% | -17.41% | 59.01% | 43.09% | 50.95% |
| EPS Basic | 4.92% | -17.73% | 43.77% | 65.15% | 7.41% |
| Normalized Basic EPS | 7.61% | -24.49% | 52.99% | 32.73% | -0.19% |
| EPS Diluted | 7.17% | -14.29% | 48.98% | 62.00% | 5.52% |
| Normalized Diluted EPS | 11.21% | -21.62% | 57.68% | 30.70% | -3.29% |
| Average Basic Shares Outstanding | 0.04% | -0.16% | 1.04% | 0.44% | -0.71% |
| Average Diluted Shares Outstanding | -3.21% | -3.82% | -1.99% | 2.01% | 2.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
